Zealand Pharma Signs Licensing Agreement with Novo Nordisk for Zegalogue®
By Ayush Saxena
Pharma Deals Review: Vol 2022 Issue 9 (Table of Contents)
Published: 21 Sep-2022
DOI: 10.3833/pdr.v2022.i9.2722 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Zealand Pharma has entered into a global license and development agreement with Novo Nordisk to commercialise its low blood sugar therapy, Zegalogue®(dasiglucagon), for injection...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS